Ryan K. Bachtell

Ryan K. Bachtell

Auto-generated profile, based on publicly available information

Ryan K. Bachtell

University of Colorado Boulder

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2007 in Nature Neuroscience
Verified
Journal Article
Closed access
DGDanielle L Graham
Danielle L Graham
SEScott Edwards
Scott Edwards
RBRyan K Bachtell
Ryan K Bachtell
RDRalph J DiLeone
Ralph J DiLeone
MRMaribel Rios
Maribel Rios
DSDavid W Self
David W Self

15 August 2012 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
MHMark R Hutchinson
Mark R Hutchinson
ANA. L. Northcutt
A. L. Northcutt
THT. Hiranita
T. Hiranita
XWXiaohui Wang
Xiaohui Wang
SLS. S. Lewis
S. S. Lewis
LWL. R. Watkins
L. R. Watkins
Opioid action was thought to exert reinforcing effects solely via the initial agonism of opioid receptors. Here, we present evidence for an additional novel contributor to opioid reward: the innate immune pattern-recognition receptor, toll-like receptor 4 (TLR4), and its MyD88-dependent signaling. Blockade of TLR4/MD2 by administration of the nonopioid, unnatural isomer of naloxone, (+)-naloxone (rats), or two independent genetic knock-outs of MyD88-TLR4-dependent signaling (mice), suppressed opioid-induced conditioned place preference. (+)-Naloxone also reduced opioid (remifentanil) self-administration (rats), another commonly used behavioral measure of drug reward. Moreover, pharmacological blockade of morphine-TLR4/MD2 activity potently reduced morphine-induced elevations of extracellular dopamine in rat nucleus accumbens, a region critical for opioid reinforcement. Importantly, opioid-TLR4 actions are not a unidirectional influence on opioid pharmacodynamics, sinceTLR4−/−mice had reduced oxycodone-induced p38 and JNK phosphorylation, while displaying potentiated analgesia. Similar to our recent reports of morphine-TLR4/MD2 binding, here we provide a combination ofin silicoand biophysical data to support (+)-naloxone and remifentanil binding to TLR4/MD2. Collectively, these data indicate that the actions of opioids at classical opioid receptors, together with their newly identified TLR4/MD2 actions, affect the mesolimbic dopamine system that amplifies opioid-induced elevations in extracellular dopamine levels, therefore possibly explaining altered opioid reward behaviors. Thus, the discovery of TLR4/MD2 recognition of opioids as foreign xenobiotic substances adds to the existing hypothesized neuronal reinforcement mechanisms, identifies a new drug target in TLR4/MD2 for the treatment of addictions, and provides further evidence supporting a role for central proinflammatory immune signaling in drug reward.

3 February 2015 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
ANA L Northcutt
A L Northcutt
MHMark R Hutchinson
Mark R Hutchinson
XWX Wang
X Wang
MBM V Baratta
M V Baratta
THT Hiranita
T Hiranita
LWL R Watkins
L R Watkins
The initial reinforcing properties of drugs of abuse, such as cocaine, are largely attributed to their ability to activate the mesolimbic dopamine system. Resulting increases in extracellular dopamine in the nucleus accumbens (NAc) are traditionally thought to result from cocaine’s ability to block dopamine transporters (DATs). Here we demonstrate that cocaine also interacts with the immunosurveillance receptor complex, Toll-like receptor 4 (TLR4), on microglial cells to initiate central innate immune signaling. Disruption of cocaine signaling at TLR4 suppresses cocaine-induced extracellular dopamine in the NAc, as well as cocaine conditioned place preference and cocaine self-administration. These results provide a novel understanding of the neurobiological mechanisms underlying cocaine reward/reinforcement that includes a critical role for central immune signaling, and offer a new target for medication development for cocaine abuse treatment.

27 February 2008 in Synapse
Verified
Journal Article
Closed access
PDF file
LPL.I. Perrotti
L.I. Perrotti
RWR.R. Weaver
R.R. Weaver
BRB. Robison
B. Robison
WRW. Renthal
W. Renthal
IMI. Maze
I. Maze
ENE.J. Nestler
E.J. Nestler

15 September 2005 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
RBRyan K. Bachtell
Ryan K. Bachtell
KWKimberly Whisler
Kimberly Whisler
DKDavid Karanian
David Karanian
DSDavid W. Self
David W. Self

1 November 1999 in Brain Research
Verified
Journal Article
Closed access
RBRyan K Bachtell
Ryan K Bachtell
YWYuan-Mei Wang
Yuan-Mei Wang
PFPierre Freeman
Pierre Freeman
FRFred O Risinger
Fred O Risinger
ARAndrey Ryabinin
Andrey Ryabinin